Advertisement
Singapore markets closed

  • Straits Times Index

    3,264.53
    -35.51 (-1.08%)
     

  • S&P 500

    5,170.21
    -17.49 (-0.34%)
     

  • Dow

    38,883.08
    -1.18 (-0.00%)
     

  • Nasdaq

    16,238.56
    -93.99 (-0.58%)
     

  • Bitcoin USD

    61,918.05
    -1,726.50 (-2.71%)
     

  • CMC Crypto 200

    1,321.23
    +26.56 (+2.06%)
     

  • FTSE 100

    8,338.12
    +24.45 (+0.29%)
     

  • Gold

    2,319.40
    -4.80 (-0.21%)
     

  • Crude Oil

    77.73
    -0.65 (-0.83%)
     

  • 10-Yr Bond

    4.4940
    +0.0310 (+0.69%)
     

  • Nikkei

    38,202.37
    -632.73 (-1.63%)
     

  • Hang Seng

    18,313.86
    -165.51 (-0.90%)
     

  • FTSE Bursa Malaysia

    1,604.75
    -0.93 (-0.06%)
     

  • Jakarta Composite Index

    7,088.79
    -34.82 (-0.49%)
     

  • PSE Index

    6,659.18
    +40.60 (+0.61%)
     

T2 Biosystems to Report First Quarter 2024 Financial Results and Business Updates on May 6, 2024

T2 Biosystems, Inc.
·1-min read
T2 Biosystems, Inc.
T2 Biosystems, Inc.

LEXINGTON, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the first quarter 2024 and business updates after market close on Monday, May 6, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the Events & Presentations section. To listen to the conference call, please dial 1-888-506-0062 (US/Canada) or 1-973-528-0011 (International), passcode 160751, approximately ten to five minutes prior to the start time.

About T2 Biosystems

T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel, the T2Resistance® Panel, and the T2Biothreat™ Panel, and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the U.S. T2Resistance Panel, the Candida auris test, and the T2Lyme™ Panel. For more information, please visit www.t2biosystems.com.

Investor Contact:
Philip Trip Taylor, Gilmartin Group
ir@T2Biosystems.com
415-937-5406